RadioBDC Logo
Youth Without Youth | Metric Listen Live
THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Gilead and J&J expand HIV cocktail partnership

November 15, 2011

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

NEW YORK—Gilead Sciences Inc. and Johnson & Johnson's Tibotec unit said Tuesday they will collaborate to develop a new HIV pill that combines Tibotec's Prezista with Gilead's drug Emtriva and two experimental drugs.

The tablet would also include Gilead's drug candidates cobicistat and GS 7340, which have not yet been approved. The companies said Gilead will be responsible for manufacturing the drug, and for handling the regulatory process and sales if it is approved. Tibotec will have the right to co-market the drug in some countries.

The agreement completes a deal the companies announced in June: Gilead and Tibotec said they would collaborate on a pill that combines Prezista with cobicistat.

Gilead and Tibotec also developed the two-in-one HIV drug Complera, which was approved in August. Complera combines Gilead's drug Truvada with Johnson & Johnson's Edurant.

Shares of Gilead rose 21 cents to close at $40.67 Tuesday and were unchanged after hours. Johnson and Johnson shares edged up 8 cents during the day and ended at $64.99 and were unchanged after hours.